Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is China Medical System Holdings Days Payable?
China Medical System HoldingsCHSYF +0.11%87 Days Payable is 17.89 as of Dec. 2025, which is 28% below its 10-year median of 24.76. GuruFocus rates CHSYF with a GF Score™ of 87/100 and a GF Value™ of $1.30 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 926 Drug Manufacturers companies, China Medical System Holdings ranks worse than 95.57% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's Days Payable falls into.
China Medical System Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings (CHSYF) has a Days Payable of 17.89 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Medical System Holdings and its competitors. This is 28% below median its historical median of 24.76. Over the past decade, China Medical System Holdings' Days Payable has ranged from 17.74 to 31.00. According to the industry distribution chart, China Medical System Holdings ranks #885 out of 926 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is China Medical System Holdings' Days Payable too high?
China Medical System Holdings' current Days Payable of 17.89 is 28% below median its 10-year median of 24.76. Over the past 10 years, this metric has ranged from a low of 17.74 to a high of 31.00. The Drug Manufacturers industry median Days Payable is 90.22. China Medical System Holdings' value of 17.89 is 80.2% below this industry median. Based on the distribution chart, China Medical System Holdings ranks #885 out of 926 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Medical System Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Medical System Holdings ranks #885 out of 926 companies for Days Payable. This places China Medical System Holdings in the lower half of its industry. The industry median Days Payable is 90.22. China Medical System Holdings' value of 17.89 is 80.2% below this benchmark. Historically, China Medical System Holdings' own Days Payable has ranged from 17.74 to 31.00 over the past decade. While the company's 10-year median is 24.76 vs. the industry median of 90.22, China Medical System Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Medical System Holdings's current Days Payable of 17.89 is 80.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Medical System Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Medical System Holdings's current Days Payable is 17.89, which is 28% below median its own 10-year median of 24.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (CHSYF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.30, compared to a current price of $1.57 — trading 20.8% above its estimated fair value. The current Days Payable is 17.89, which is 28% below median its 10-year median of 24.76 and 80.2% below the Drug Manufacturers industry median of 90.22. China Medical System Holdings' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China Medical System Holdings (CHSYF), the current Days Payable is 17.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (CHSYF) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be overvalued.
The current stock price of $1.57 is trading 20.8% above its estimated GF Value™ of $1.30.
GuruFocus considers China Medical System Holdings to be Modestly Overvalued.
Key valuation signals for CHSYF:
Days Payable: 17.89 (28% below median its 10-year median of 24.76)
GF Value™: $1.30 vs. price of $1.57 (20.8% above fair value)
Industry Position: 80.2% below the Drug Manufacturers median (#885 of 926)
No single metric tells the full story. See the CHSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Business Description
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
87GF Score
Get the complete analysis for CHSYF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHSYF has been successfully added to your 
